This article is part of a Chronicle. See more from this Chronicle
Lauren Battaglia, Apr 29, 2014
In June 2013, the Supreme Court ruled in FTC v. Actavis that reverse-payment pharmaceutical patent settlement agreements are subject to rule of reason analysis under the antitrust laws. In doing so, the Court not only rejected both the FTC’s position that such agreements should be presumptively unlawful and the position of pharmaceutical manufacturers that such agreements should only be subject
...THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 18.191.223.123
Please verify email or join us to access premium content!